685 related articles for article (PubMed ID: 2521457)
1. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
2. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.
Ochoa AC; Gromo G; Alter BJ; Sondel PM; Bach FH
J Immunol; 1987 Apr; 138(8):2728-33. PubMed ID: 2435804
[TBL] [Abstract][Full Text] [Related]
3. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
4. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
7. CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors.
Dianzani U; Zarcone D; Pistoia V; Grossi CE; Pileri A; Massaia M; Ferrarini M
Eur J Immunol; 1989 Jun; 19(6):1037-44. PubMed ID: 2502419
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
Anderson PM; Bach FH; Ochoa AC
Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
[TBL] [Abstract][Full Text] [Related]
9. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
Schwarz RE; Hiserodt JC
J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
[TBL] [Abstract][Full Text] [Related]
10. Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits.
Geller RL; Smyth MJ; Strobl SL; Bach FH; Ruscetti FW; Longo DL; Ochoa AC
J Immunol; 1991 May; 146(10):3280-8. PubMed ID: 1673980
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
14. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
16. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
17. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.
Vujanovic NL; Rabinowich H; Lee YJ; Jost L; Herberman RB; Whiteside TL
Cell Immunol; 1993 Oct; 151(1):133-57. PubMed ID: 8402925
[TBL] [Abstract][Full Text] [Related]
18. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
19. A novel surface molecule expressed by long-term cultured T and natural killer cells is involved in cell activation.
Ferrini S; Cantoni C; Ciccone E; Biassoni R; Prigione I; Bottino C; Venzano P; Moretta L
Eur J Immunol; 1991 Sep; 21(9):1981-7. PubMed ID: 1832383
[TBL] [Abstract][Full Text] [Related]
20. Generation of lymphokine-activated killer cell activity from human thymocytes.
Ramsdell FJ; Golub SH
J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]